Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Mechanistic Study of GSK3196165 with Methotrexate in Active Rheumatoid Arthritis
2015-004386-91Phase 2Completed
- Sponsor
- GSK
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA), sponsored by GSK. Primary endpoint: Changes from baseline in exploratory biomarkers. Started May 2016; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-004386-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004386-91.